Cryoglobulinemia is a condition in which abnormal proteins in your blood, called cryoglobulins, clump together when exposed to cold temperatures and dissolve again when warmed back to body temperature. When these protein clumps deposit on blood vessel walls, they can trigger inflammation, block small vessels, and damage organs throughout the body. The condition ranges from a silent lab finding with no symptoms to a serious, multi-organ disease called cryoglobulinemic vasculitis.
How Cryoglobulins Cause Damage
Cryoglobulins are immune system proteins (immunoglobulins) that behave abnormally. At normal body temperature, they stay dissolved in the bloodstream. But in cooler parts of the body, like the skin of the fingers, toes, nose, and ears, they precipitate out of the blood and stick to blood vessel walls. This triggers two problems at once: the clumps physically obstruct small vessels, reducing blood flow, and they activate the immune system’s inflammatory response, damaging the vessel lining. The result is a form of vasculitis, or blood vessel inflammation, that can affect the skin, kidneys, nerves, and joints.
The Three Types
Cryoglobulinemia is classified into three types based on the kinds of immune proteins involved, a system first proposed in 1974.
Type I involves a single type of monoclonal immunoglobulin, most often IgM. It develops in people with blood cancers or related disorders like multiple myeloma, Waldenström macroglobulinemia, or a precancerous condition called monoclonal gammopathy of undetermined significance (MGUS). Type I tends to cause problems by thickening the blood and blocking vessels rather than triggering widespread inflammation. In some patients, blood viscosity rises high enough to cause hyperviscosity syndrome, with symptoms like blurred vision, headaches, and confusion. Symptoms typically appear when blood viscosity exceeds about three times that of water.
Types II and III are grouped together as “mixed cryoglobulinemia” because the clumps contain a mix of different immunoglobulin types, including one that acts as an autoantibody (an immune protein that mistakenly attacks other immune proteins). The distinction between the two is technical: Type II contains a monoclonal autoantibody, while Type III contains only polyclonal ones. Both types cause similar symptoms and are strongly linked to infections, autoimmune diseases, and sometimes blood cancers. About 10% of mixed cryoglobulinemia cases have no identifiable cause and are labeled “essential.”
Hepatitis C Is the Leading Cause
Hepatitis C virus (HCV) infection is by far the most common trigger for mixed cryoglobulinemia. Between 40% and 60% of people with chronic hepatitis C have detectable cryoglobulins in their blood, though only 5% to 10% of them develop actual symptoms of cryoglobulinemic vasculitis. The virus appears to chronically stimulate B cells (a type of immune cell), leading to overproduction of the abnormal proteins.
Other infections linked to mixed cryoglobulinemia include hepatitis B and HIV. Autoimmune diseases, particularly lupus and Sjögren syndrome, are also well-recognized causes. Type I, by contrast, is almost always tied to a blood cell disorder rather than an infection.
Symptoms and the Meltzer Triad
The classic presentation of mixed cryoglobulinemia is a combination of three symptoms known as Meltzer’s triad: purpura (small reddish-purple spots on the skin, especially the legs), joint pain, and general weakness. Purpura occurs because inflamed blood vessels leak red blood cells into the skin. It often appears on the lower legs after standing or walking and can leave brownish stains that persist for weeks.
Raynaud’s phenomenon, where fingers or toes turn white or blue in cold temperatures, is also common in Types II and III. The connection to cold exposure makes intuitive sense: cold is what causes the proteins to clump in the first place.
Kidney Involvement
The kidneys are one of the most seriously affected organs, particularly in Types II and III. Cryoglobulin deposits in the kidney’s tiny filtering units cause a pattern of damage called membranoproliferative glomerulonephritis, where the filters become inflamed and thickened. Signs include protein or blood in the urine, rising blood pressure, and declining kidney function. Without treatment, this can progress to kidney failure.
Nerve Damage
Peripheral neuropathy, damage to nerves outside the brain and spinal cord, is more frequent in Types II and III. It typically starts as numbness, tingling, or burning pain in the feet and hands. Some people develop weakness in the legs. The nerve damage happens because inflamed small blood vessels cut off the nerve’s blood supply.
How It’s Diagnosed
Diagnosing cryoglobulinemia requires a specialized blood test, and the way the sample is handled matters enormously. Blood must be drawn into tubes that have been pre-warmed to body temperature (37°C) and transported to the lab without cooling. If the sample gets cold before it reaches the lab, the cryoglobulins precipitate out during transport and are lost, leading to a false-negative result. This is one of the most common reasons cryoglobulinemia goes undetected.
Once at the lab, the blood is allowed to clot at 37°C, and the serum is then refrigerated for up to seven days. If a visible precipitate forms and dissolves again when rewarmed, cryoglobulins are confirmed. The amount of precipitate, measured as a “cryocrit” (similar to a hematocrit), gives a rough sense of the protein burden. Further testing identifies which immunoglobulin types are present, which determines whether you have Type I, II, or III.
Additional blood work typically shows low levels of a protein called C4 (part of the complement system), elevated rheumatoid factor, and sometimes signs of kidney dysfunction. If kidney involvement is suspected, a biopsy can confirm the characteristic pattern of damage.
Treatment Depends on the Type and Cause
Treatment is only needed when cryoglobulinemia causes symptoms. Many people have detectable cryoglobulins without any signs of disease, and they generally just need monitoring.
Type I
Because Type I is driven by an underlying blood disorder, treatment targets that disorder. The specific approach depends on which organs are affected. For patients with kidney problems, regimens built around certain targeted cancer therapies are preferred. For those with nerve damage, different drug combinations work better. Steroids, sometimes at high doses, are often part of initial treatment, especially for MGUS-related cases. A targeted therapy called rituximab, which depletes the B cells responsible for making the abnormal protein, can be added after an initial response, though using it too early in IgM-type disease risks a temporary spike in the protein that can worsen symptoms.
Mixed Cryoglobulinemia (Types II and III)
For hepatitis C-related cases, antiviral treatment to eliminate the virus is the cornerstone. Clearing the infection removes the stimulus that drives cryoglobulin production. However, patients with severe organ involvement often need immunosuppressive therapy first to get the vasculitis under control before starting antivirals.
For non-infectious mixed cryoglobulinemia, or when antiviral treatment alone isn’t enough, the mainstay is immune suppression. Rituximab combined with corticosteroids has proven more effective than steroids alone, producing better clinical improvement, kidney recovery, and reduction in cryoglobulin levels. For life-threatening flares, such as rapidly worsening kidney failure or severe nerve damage, stronger immune-suppressing drugs may be combined with high-dose intravenous steroids. Plasmapheresis, a procedure that filters the abnormal proteins directly out of the blood, can provide rapid short-term relief during crises.
Long-Term Outlook
The prognosis for mixed cryoglobulinemia has improved significantly with modern treatments. In a study of 246 patients, the overall five-year survival rate was 84%, and the ten-year rate was 74%. Type III mixed cryoglobulinemia carries a somewhat better prognosis than Type II: 92% five-year survival versus 81%, and 84% versus 71% at ten years.
The main threats to long-term survival are progressive kidney disease, severe infections (partly due to immunosuppressive treatment), and the development of lymphoma. Mixed cryoglobulinemia sits at a crossroads between autoimmunity and lymphoproliferation, meaning the same chronic immune stimulation that produces cryoglobulins can, over time, push B cells toward malignancy. Regular follow-up is important for catching these complications early.